Kraig Biocraft Laboratories Enters Third Phase of Its Monster Silk(TM) Pilot Production Program Ahead of Schedule
February 28 2013 - 6:05AM
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or
"Kraig"), the leading developer of advanced spider silk based fiber
technologies, announced today the launch of stage 3 of its pilot
production program ("program").
The program is designed to run in three stages, each launching
in turn when the data from the previous stage indicates that the
program is reaching its benchmarks.
"The launch of stage three indicates stages 1 and 2 are
exceeding our expectations with hatch rates exceeding 60%. At
the current rates of the program's development, we should be able
to announce that hatchlings from the first round have begun
spinning Monster Silk™ within the next few days," said Company
founder and CEO, Kim K. Thompson.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully
reporting biotechnology company is the leading developer of
genetically engineered spider silk based fiber
technologies. The Company has achieved a series of scientific
breakthroughs in the area of spider silk technology with
implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "estimated," "hopes," "if," "develops," "researching,"
"research," "pilot," "potential," "could" or other words or phrases
of similar import. Forward looking statements include descriptions
of the Company's business strategy, outlook, objectives, plans,
intentions and goals. All such forward-looking statements are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those in forward-looking
statements.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2024 to Jun 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Jun 2023 to Jun 2024